Drug recall · January 3, 2024
AMOXICILLIN for Oral Suspension USP recall
Why: CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
AMOXICILLIN for Oral Suspension USP, 400MG/5ML, 100ML (when reconstituted), Manufactured In Canada By: TEVA CANA LIMITED, Toronto, Canada M1B 2K9; Manufactured For: TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454. NDC: 0093-4161-73
- Lots / codes
Batch 35447184A
- Quantity
- 3 units
- Company
- Cardinal Healthcare, Dublin, OH
- Distribution
- Nationwide USA
- Initiated
- January 26, 2022 · Voluntary: Firm initiated
- Classified
- December 26, 2023
- Reported
- January 3, 2024
- Ended
- September 29, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Amoxicillin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.